NHI Stock Forecast & Price Target

National Health Investors is viewed favorably because it is repositioning away from a low-growth, legacy NHC relationship and toward a higher-quality mix of accretive acquisitions and SHOP expansion, which should support stronger organic growth over time. The planned $560 million sale of the 35-facility NHC portfolio, combined with expected debt repayment that could reduce leverage from 3.8x debt/EBITDA to about 2.3x pro forma, creates substantial dry powder of roughly $350 million to $500 million+ and improves financial flexibility, while modeled SHOP occupancy rising from 86.6% at 1Q26 to 88.3% at the end of 2026 and 89.5% at the end of 2027 signals a meaningful operating recovery. Even with near-term dilution that lowers 2026 FFO to $4.72 per share and 2027 FFO to $5.17 per share, the stock’s valuation at 15x 2026E FFO and 14.5x 2026E FAD, alongside a 5.1% projected dividend yield and implied 17.7% total return, suggests the market is not fully reflecting the improved balance sheet and longer-term growth runway.

National Health Investors is facing a negative fundamental outlook because the expected near-term benefits from the NHC portfolio sale have not materialized into an immediate rent reset, and management now expects total annual NOI to fall from $313 million as of 12/31/25 to $273 million pro forma due to the loss of NHC rental income. The company is also being pressured by lower FFO expectations, including non-cash write-offs such as a $1,452 straight-line rent receivable adjustment and increased reliance on redeploying sale proceeds, while modeled 2026 and 2027 equity issuance of $45 million and $98 million suggests dilution and execution risk. Although the balance sheet is described as low-levered, the stock still trades at 16.7x FactSet consensus 2026E AFFO and a 52% premium to FactSet consensus NAV, leaving it vulnerable if operator concentration, government reimbursements, acquisition pricing, or interest rates move unfavorably.